Complexity of Genomic Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Isolates in Colombia Urges the Reinforcement of Whole Genome Sequencing-Based Surveillance Programs
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Complexity of Genomic Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Isolates in Colombia Urges the Reinforcement of Whole Genome Sequencing-Based Surveillance Programs. / Saavedra, S.Y.; Bernal, J.F.; Montilla-Escudero, E.; Arévalo, S.A.; Prada, D.A.; Valencia, M.F.; Moreno, J.; Hidalgo, A.M.; Garciá-Vega, Á.S.; Abrudan, M.; Argimón, S.; Kekre, M.; Aanensen, D.M.; Duarte, C.; Donado-Godoy, P.; Abudahab, K.; Harste, H.; Muddyman, D.; Taylor, B.; Wheeler, N.; Beltran, G.; Delgadillo, F.; Osma, E.C.D.; Ravikumar, K.L.; Nagaraj, G.; Shamanna, V.; Govindan, V.; Prabhu, A.; Sravani, D.; Shincy, M.R.; Ravishankar, K.N.; Okeke, I.N.; Oaikhena, A.O.; Afolayan, A.O.; Ajiboye, J.J.; Ewomazino Odih, E.; Carlos, C.; Lagrada, M.L.; Macaranas, P.K.V.; Olorosa, A.M.; Gayeta, J.M.; Herrera, E.M.; Molloy, A.; Stelling, J.; Vegvari, C.
In: Clinical Infectious Diseases, Vol. 73, No. 5, 2021, p. 866-872.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Complexity of Genomic Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Isolates in Colombia Urges the Reinforcement of Whole Genome Sequencing-Based Surveillance Programs
AU - Saavedra, S.Y.
AU - Bernal, J.F.
AU - Montilla-Escudero, E.
AU - Arévalo, S.A.
AU - Prada, D.A.
AU - Valencia, M.F.
AU - Moreno, J.
AU - Hidalgo, A.M.
AU - Garciá-Vega, Á.S.
AU - Abrudan, M.
AU - Argimón, S.
AU - Kekre, M.
AU - Aanensen, D.M.
AU - Duarte, C.
AU - Donado-Godoy, P.
AU - Abudahab, K.
AU - Harste, H.
AU - Muddyman, D.
AU - Taylor, B.
AU - Wheeler, N.
AU - Beltran, G.
AU - Delgadillo, F.
AU - Osma, E.C.D.
AU - Ravikumar, K.L.
AU - Nagaraj, G.
AU - Shamanna, V.
AU - Govindan, V.
AU - Prabhu, A.
AU - Sravani, D.
AU - Shincy, M.R.
AU - Ravishankar, K.N.
AU - Okeke, I.N.
AU - Oaikhena, A.O.
AU - Afolayan, A.O.
AU - Ajiboye, J.J.
AU - Ewomazino Odih, E.
AU - Carlos, C.
AU - Lagrada, M.L.
AU - Macaranas, P.K.V.
AU - Olorosa, A.M.
AU - Gayeta, J.M.
AU - Herrera, E.M.
AU - Molloy, A.
AU - Stelling, J.
AU - Vegvari, C.
PY - 2021
Y1 - 2021
N2 - Background: The recommended duration of antimicrobial treatment for Staphylococcus aureus bacteremia (SAB) is a minimum of 14 days. We compared the clinical outcomes of patients receiving short-course (SC; 6-10 days), or prolonged-course (PC; 11-16 days) antibiotic therapy for low-risk methicillin-susceptible SAB (MS-SAB).Methods: Adults with MS-SAB in 1995-2018 were included from 3 independent retrospective cohorts. Logistic regression models fitted with inverse probability of treatment weighting were used to assess the association between the primary outcome of 90-day mortality and treatment duration for the individual cohorts as well as a pooled cohort analysis.Results: A total of 645, 219, and 141 patients with low-risk MS-SAB were included from cohorts I, II, and III. Median treatment duration in the 3 SC groups was 8 days (interquartile range [IQR], 7-10), 9 days (IQR, 8-10), and 8 days (IQR, 7-10). In the PC groups, patients received a median therapy of 14 days (IQR, 13-15), 14 days (IQR, 13-15), and 13 days (IQR, 12-15). No significant differences in 90-day mortality were observed between the SC and PC group in cohort I (odds ratio [OR], 0.85 [95% confidence interval {CI}, .49-1.41]), cohort II (OR, 1.24 [95% CI, .60-2.62]), or cohort III (OR, 1.15 [95% CI, .24-4.01]). This result was consistent in the pooled cohort analysis (OR, 1.05 [95% CI, .71-1.51]). Furthermore, duration of therapy was not associated with the risk of relapse.Conclusions: In patients with low-risk MS-SAB, shorter courses of antimicrobial therapy yielded similar clinical outcomes as longer courses of therapy.
AB - Background: The recommended duration of antimicrobial treatment for Staphylococcus aureus bacteremia (SAB) is a minimum of 14 days. We compared the clinical outcomes of patients receiving short-course (SC; 6-10 days), or prolonged-course (PC; 11-16 days) antibiotic therapy for low-risk methicillin-susceptible SAB (MS-SAB).Methods: Adults with MS-SAB in 1995-2018 were included from 3 independent retrospective cohorts. Logistic regression models fitted with inverse probability of treatment weighting were used to assess the association between the primary outcome of 90-day mortality and treatment duration for the individual cohorts as well as a pooled cohort analysis.Results: A total of 645, 219, and 141 patients with low-risk MS-SAB were included from cohorts I, II, and III. Median treatment duration in the 3 SC groups was 8 days (interquartile range [IQR], 7-10), 9 days (IQR, 8-10), and 8 days (IQR, 7-10). In the PC groups, patients received a median therapy of 14 days (IQR, 13-15), 14 days (IQR, 13-15), and 13 days (IQR, 12-15). No significant differences in 90-day mortality were observed between the SC and PC group in cohort I (odds ratio [OR], 0.85 [95% confidence interval {CI}, .49-1.41]), cohort II (OR, 1.24 [95% CI, .60-2.62]), or cohort III (OR, 1.15 [95% CI, .24-4.01]). This result was consistent in the pooled cohort analysis (OR, 1.05 [95% CI, .71-1.51]). Furthermore, duration of therapy was not associated with the risk of relapse.Conclusions: In patients with low-risk MS-SAB, shorter courses of antimicrobial therapy yielded similar clinical outcomes as longer courses of therapy.
U2 - 10.1093/cid/ciab777
DO - 10.1093/cid/ciab777
M3 - Journal article
C2 - 34850835
VL - 73
SP - 866
EP - 872
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 5
ER -
ID: 323555161